Company Overview and News
San Antonio, Texas, June 06, 2018 (GLOBE NEWSWIRE) -- U.S. Global Investors, Inc. (NASDAQ: GROW), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, will continue its payment of monthly dividends in the first fiscal quarter of 2019.
San Antonio, Texas, June 01, 2018 (GLOBE NEWSWIRE) -- U.S. Global Investors, Inc. (NASDAQ: GROW), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, announced today the resignation of Susan McGee as President, General Counsel and Chief Compliance Officer.
The following slide deck was published by U.S. Global Investors, Inc. in conjunction with their 2018 Q3 earnings call.
SAN ANTONIO–May 10, 2018–U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, today reported a net loss of $1.1 million, or $0.07 per share for the quarter ended March 31, 2018. For the nine-month period, however, net income was $959,000, or $0.06 per share, an increase of more than 300 percent compared to the same period last year.
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#8O2VED7!E+T=R;W5P+U,O5')A M;G-P87)E;F-Y+T-3+T1E=FEC95)'0CX^+U1A8G,O4R]3=')U8W1087)E;G1S M(# ^/@T*96YD;V)J#0HT(# @;V)J#0H\/"]&:6QT97(O1FQA=&5$96-O9&4O M3&5N9W1H(#(X,3<^/@T*
San Antonio, Texas, March 26, 2018 (GLOBE NEWSWIRE) -- U.S. Global Investors, Inc. (NASDAQ: GROW), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, will continue its payment of monthly dividends in the fourth fiscal quarter of 2018.
In the world of bitcoin, blockchain and cryptocurrency trading, there has been a story that went from rags to riches and back to rags in a pretty short time. The underlying technology is of course set to remain in place. Still, many investors and speculators think that bitcoin itself and the subsequent cryptocurrencies are just the next bubble.
OSTK RIOT SCRID LBCC SQ SQNXF SRAX SCRI MARA LTEA GROW DPW
2018-05-22 - Wilton
Promote Your Articles on Fintel Over 300,000 smart investors trust Fintel every month to get the latest stock market news and information. If you own or operate a web site, putting a "Share on Fintel" button on your site is a great way to promote your content to our audience. Adding the Button To install the share button, use the following code: Square Button <a href="https://fintel.io/share" onclick="window.location = 'https://fintel.io/share?url=' + encodeURIComponent(window.location); return false"><img src="https://fintel.io/images/fintel-f-logo.png" width="50" /> </a> Round Button <a href="https://fintel.io/share" onclick="window.location = 'https://fintel.io/share?url=' + encodeURIComponent(window.location); return false"><img src="https://fintel...
4h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
Silicon Investor Message Boards
This table lists all message boards related to GROW / U.S. Global Investors, Inc. on message board site Silicon Investor.
as of ET